TimeTeller GmbH

TimeTeller® combines research results on molecular interactions of the internal biological clock with clock-controlled genes and their impact in diseases. TimeTeller® is a spin-off of the Charité Universitätsmedizin Berlin and builds upon the research of the Circadian Medicine and Systems Biology research group lead by Angela Relógio.

TimeTeller® as a project was initially funded by „Inventors for Health“ (I4H)-program by the Stiftung Charité and later by the Digital Health Accelerator (DHA) from the Berlin Institute of Health (BIH). Within these programs a medical device was developed. Benjamin Dose joined the TimeTeller® project at this stage to support the team amongst others in regulatory matters. In March 2023 TimeTeller® was founded as a GmbH by Angela Relógio, the Ascenion GmbH (the technology transfer partner of Charité) and Benjamin Dose.

At TimeTeller®, our goal is to empower individuals and healthcare professionals with knowledge and tools to optimize health and prevent diseases through understanding and applying the power of circadian rhythms.

We aim to play a crucial role in the field of pharmacological research and drug development by using the knowledge of circadian rhythms to optimize drug efficacy and diminish toxicity. By working with scientists of different research fields and pharmaceutical companies, we want to integrate circadian rhythm-based interventions into drug development processes, ultimately leading to more effective treatments for a variety of diseases.

Our ultimate goal is to make circadian rhythm-based interventions an integral part of healthcare and enable individuals to live healthier, and more enjoyable lives.